Safety of Intravitreal Injection of Biosimilar of Aflibercept in Rabbit Eyes

Safety of Intravitreal Injection of Biosimilar of Aflibercept in Rabbit Eyes Publisher

Lashay A¹ ; Riaziesfahani H¹ ; Faghihi H¹ ; Mirshahi A¹ ; Khojasteh H¹ ; Khodabande A¹ ; Amoli FA¹ ; Ghassemi F¹ ; Bazvand F¹ ; Khalili Pour E¹ ; Ebrahimiadib N¹ ; Torkashvand A¹ ; Delrish E¹

Show Affiliations

1. Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Ophthalmology Published:2020

Abstract

Purpose. To assess the safety of biosimilar intravitreal aflibercept (CinnaGen Co., Iran) compared to the reference product (Eylea®; Bayer Schweiz AG, Zurich, Switzerland) in rabbit eyes through functional and histologic studies. Methods. Forty New Zealand albino rabbits were recruited to the study and were divided into four groups to be sacrificed at 48 hours, one, two, and four weeks after injections. In each group, five rabbits received 0.05 mL (2 mg) biosimilar aflibercept in the right eye and 0.05 mL saline in the left eye as the control, and in a similar manner, the remaining five rabbits received the reference drug in the right eye and saline in the left eye. All the rabbits underwent comprehensive ophthalmic examination and electroretinography (ERG) tests at baseline and also just before enucleation at the specific predefined time points. The enucleated eyes were prepared for retinal toxicity histological examination. Results. No retinal toxicity was observed based on histologic and ERG findings in all groups. Choroidal congestion was revealed after 1 week in an eye that was injected with biosimilar aflibercept, although the similar finding was detected in the contralateral eye which received saline. Also, one subject which received the reference drug showed chronic vitritis and lymphoplasmocytic reaction of the optic disc at week 4. The remaining subjects showed no histologic changes. Conclusion. The 2 mg intravitreal injection of biosimilar aflibercept (CinnaGen Co., Iran) was found to be nontoxic in rabbit eyes in the short-term period. Further studies are required to warrant the efficacy and safety profile of the drug in human subjects. © 2020 Alireza Lashay et al.

Related Docs

1. Safety of Intravitreal Injection of Stivant, a Biosimilar to Bevacizumab, in Rabbit Eyes, Journal of Ophthalmic and Vision Research (2020)

2. Monoclonal Antibodies in Diabetic Retinopathy, Expert Review of Clinical Immunology (2022)

Experts (# of related papers)

View all Related Experts

Elias Khalilipour (1)

Nima Rezaei (1)

Style	Citing Format
MLA	Lashay A, et al.. "Safety of Intravitreal Injection of Biosimilar of Aflibercept in Rabbit Eyes." Journal of Ophthalmology, vol. 2020, no. , 2020, pp. -.
APA	Lashay A, Riaziesfahani H, Faghihi H, Mirshahi A, Khojasteh H, Khodabande A, Amoli FA, Ghassemi F, Bazvand F, Khalili Pour E, Ebrahimiadib N, Torkashvand A, Delrish E (2020). Safety of Intravitreal Injection of Biosimilar of Aflibercept in Rabbit Eyes. Journal of Ophthalmology, 2020(), -.
Chicago	Lashay A, Riaziesfahani H, Faghihi H, Mirshahi A, Khojasteh H, Khodabande A, Amoli FA, et al.. "Safety of Intravitreal Injection of Biosimilar of Aflibercept in Rabbit Eyes." Journal of Ophthalmology 2020, no. (2020): -.
Harvard	Lashay A et al. (2020) 'Safety of Intravitreal Injection of Biosimilar of Aflibercept in Rabbit Eyes', Journal of Ophthalmology, 2020(), pp. -.
Vancouver	Lashay A, Riaziesfahani H, Faghihi H, Mirshahi A, Khojasteh H, Khodabande A, et al.. Safety of Intravitreal Injection of Biosimilar of Aflibercept in Rabbit Eyes. Journal of Ophthalmology. 2020;2020():-.
BibTex	@article{ author = {Lashay A and Riaziesfahani H and Faghihi H and Mirshahi A and Khojasteh H and Khodabande A and Amoli FA and Ghassemi F and Bazvand F and Khalili Pour E and Ebrahimiadib N and Torkashvand A and Delrish E}, title = {Safety of Intravitreal Injection of Biosimilar of Aflibercept in Rabbit Eyes}, journal = {Journal of Ophthalmology}, volume = {2020}, number = {}, pages = {-}, year = {2020} }
RIS	TY - JOUR AU - Lashay A AU - Riaziesfahani H AU - Faghihi H AU - Mirshahi A AU - Khojasteh H AU - Khodabande A AU - Amoli FA AU - Ghassemi F AU - Bazvand F AU - Khalili Pour E AU - Ebrahimiadib N AU - Torkashvand A AU - Delrish E TI - Safety of Intravitreal Injection of Biosimilar of Aflibercept in Rabbit Eyes JO - Journal of Ophthalmology VL - 2020 IS - SP - EP - PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract